Marina Biotech Announces That Licensee ProNAi Therapeutics

Marina Biotech Announces That Licensee ProNAi Therapeutics Reported
Phase 1 Study Results Using SMARTICLES(R) Nucleic Acid Delivery
SMARTICLES Efficiently and Effectively Delivers Oncology
Oligonucleotide Therapeutic 
BOTHELL, WA -- (Marketwire) -- 12/05/12 --  Marina Biotech, Inc.
(PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and
development company, today announced that the Company's licensee,
ProNAi Therapeutics, has reported results of their Phase 1 study of
PNT2258, an anti-Bcl-2 cancer drug which uses the Company's
SMARTICLES delivery technology. PNT2258 targets Bcl-2-driven tumors
such as diffuse large B-cell lymphoma, follicular lymphoma and
chronic lymphocytic leukemia. The data were presented at the annual
Symposium on Molecular Targets and Cancer Therapeutics jointly hosted
by the European Organization for Research and Treatment of Cancer,
The National Cancer Institute and the American Association for Cancer
ProNAi Therapeutics reported statistically significant,
dose-dependent, and specific knockdown of the Bcl-2 gene with
suppression of protein levels up to 60 percent. Patients received the
drug for extended periods of time without having material side
effects as seen with other anti-Bcl-2 drugs or nucleic acid cancer
drugs in development. The results indicate that the drug can be
administered as either a single agent or potentially in combination
with other anti-cancer drugs without increasing patient side effects. 
"We are pleased to see the results of this ground breaking clinical
trial using our SMARTICLES delivery technology," stated Richard Ho,
M.D., Ph.D., Executive Vice President, Research and Development at
Marina Biotech. "The results suggest that SMARTICLES efficiently and
effectively delivers an oligonucleotide to tumor cells with good
safety and tolerability. We look forward to ProNAi's continued
advancement of this program and the validation of our broad nucleic
acid-based drug discovery platform." 
PNT2258 was evaluated in an open-label, single arm, Phase I
dose-escalation study in patients with advanced solid tumors for
which no standard therapy exists at START in San Antonio Texas.
PNT2258 is ProNAi's first drug candidate from its DNA interference
drug platform. Patients receive PNT2258 as an intravenous infusion
once daily for 5 consecutive days (Days 1-5) of every 21-day cycle (3
About Amphoteric Liposomes 
Amphoteric liposomes define a novel class of liposomes, which are pH
dependent charge-transitioning particles that provide for the
delivery of a nucleic acid payload (e.g., siRNA, microRNA, antisense,
decoy, etc.) to cells either by local or systemic administration.
Amphoteric liposomes are designed to release their nucleic acid
payload within the target cell where the nucleic acid can then engage
a number of biological pathways, including the RNA interference
pathway, and thereby exert a therapeutic effect. Currently, Marina
Biotech amphoteric liposomal delivery technology includes non-DiLA2
based amphoteric liposomes (or SMARTICLES(R)) and DiLA2 based
amphoteric liposomes. 
About Marina Biotech, Inc. 
Marina Biotech is a biotechnology company focused on the development
and commercialization of oligonucleotide-based therapeutics utilizing
multiple mechanisms of action including RNA interference (RNAi) and
messenger RNA translational blocking. The Marina Biotech pipeline
currently includes a clinical program in Familial Adenomatous
Polyposis (a precancerous syndrome) and two preclinical programs --
in bladder cancer and myotonic dystrophy. Marina Biotech has entered
into an agreement with both Mirna Therapeutics and ProNAi
Therapeutics to license Marina Biotech's SMARTICLES(R) technology for
the delivery of microRNA mimics and DNAi, respectively. In addition,
Marina Biotech announced exclusive licensing agreements with Monsanto
Company for Marina Biotech's delivery and chemistry technologies and
with Girindus America for the supply of CRN-based oligonucleotides.
Marina Biotech recently entered into non-exclusive agreements with
Novartis Institutes for Biomedical Research and Tekmira
Pharmaceuticals to license Marina Biotech's CRN and UNA nucleic acid
modification chemistries, respectively. Marina Biotech's goal is to
improve human health through the development of RNAi- and
oligonucleotide-based compounds and drug delivery technologies that
together provide superior therapeutic options for patients.
Additional information about Marina Biotech is available at 
Forward-Looking Statements 
Statements made in this news release may be forward-looking
statements within the meaning of Federal Securities laws that are
subject to certain risks and uncertainties and involve factors that
may cause actual results to differ materially from those projected or
suggested. Factors that could cause actual results to differ
materially from those in forward-looking statements include, but are
not limited to: (i) the ability of Marina Biotech to obtain
additional funding in the near term; (ii) the ability of Marina
Biotech to attract and/or maintain manufacturing, research,
development and commercialization partners; (iii) the ability of
Marina Biotech and/or a partner to successfully complete product
research and development, including preclinical and clinical studies
and commercialization; (iv) the ability of Marina Biotech and/or a
partner to obtain required governmental approvals; and (v) the
ability of Marina Biotech and/or a partner to develop and
commercialize products prior to, and that can compete favorably with
those of, competitors. Additional factors that could cause actual
results to differ materially from those projected or suggested in any
forward-looking statements are contained in Marina Biotech's most
recent periodic reports on Form 10-K and Form 10-Q that are filed
with the Securities and Exchange Commission. Marina Biotech assumes
no obligation to update and supplement forward-looking statements
because of subsequent events. 
Michael French
Chief Executive Officer
(425) 892-4322 
Press spacebar to pause and continue. Press esc to stop.